Republican Energy Bill Follows Massive Increase in Fossil Fuel Donations
Fossil fuel industry donors like Chevron poured $27 million into the super PAC that helped Republicans take control of the House in the midterms.
Page 37
TikTok Hires Former Biden Staffer as it Fights U.S. Ban
The company is facing pressure from U.S. lawmakers over its data practices and its ownership by a Chinese company.
Wisconsin Groups Keep It Local Amid Record Ad Blitz in Supreme Court Race
While community groups work to mobilize voters, a deluge of TV ads is set to make Wisconsin's the most expensive state supreme court race ever.
Pfizer Spends Big on IP Lobbying With Billions on the Line
The pharmaceutical giant spent big bucks amid key international negotiations last year to protect record earnings.
Intuit’s Top Lobbying Firms Are Also Major DSCC Bundlers
Congress is set to receive a report on how the IRS can streamline the tax filing process after lobbyists for Intuit bundled millions for the Senate Democrats' campaign arm.
Congressional Leaders Are Embracing Dark Money Like Never Before
Three of the four super PACs aligned with House and Senate leaders brought in record high amounts from their "dark money" affiliates in the midterms.
Biden Decision in Apple Watch Patent Dispute Could Benefit His Megadonor
Joe Kiani, CEO of medical tech company Masimo, hosted a California fundraiser for Biden when the 2020 Democratic presidential nomination contest was still a crowded field.
TikTok Owner Uses Back Door to Donate in Honor of Members of Congress
Chinese company ByteDance does not have a PAC, but it still found a way to make donations honoring hundreds of members of Congress.
Minnesota Democrats Pass Voting Rights Bill in Committee
The Democracy for the People Act, backed by a coalition of Minnesota groups, would also increase disclosure of political spending in state races.
STOCK TICKER: Blumenthal’s Wife Invests in Biotech Hedge Fund as He Chairs Panel Overseeing Drug Prices
As a consumer protection subcommittee chairman, Blumenthal has focused on the role pharmaceutical benefit managers play in driving up the cost of drugs.